NASDAQ:IRD Opus Genetics Q3 2024 Earnings Report $4.08 +0.05 (+1.24%) Closing price 04:00 PM EasternExtended Trading$4.03 -0.05 (-1.32%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Opus Genetics EPS ResultsActual EPS-$0.29Consensus EPS -$0.30Beat/MissBeat by +$0.01One Year Ago EPSN/AOpus Genetics Revenue ResultsActual Revenue$3.87 millionExpected Revenue$1.17 millionBeat/MissBeat by +$2.70 millionYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time9:00AM ETUpcoming EarningsOpus Genetics' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Opus Genetics Earnings HeadlinesOpus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease ExpertsJune 2, 2026 | globenewswire.comOpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 28, 2026 | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.June 9 at 1:00 AM | Paradigm Press (Ad)Opus Genetics to Present at the 2026 Jefferies Global Healthcare ConferenceMay 27, 2026 | globenewswire.comLeerink Partners initiates coverage of Opus Genetics (IRD) with outperform recommendationMay 22, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Opus Genetics (IRD)May 15, 2026 | theglobeandmail.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The J.M. Smucker Company’s Dividend: Too Sweet to Ignore?Has Temu-Owner PDD's Story Changed After Double Miss?Campbell's Soup Stock: Deep Value and a 7% Dividend YieldTanker Dividends Are Surging, But Income Investors Need to Watch the CycleCybersecurity Earnings: 1 AI Standout and 2 Stocks Under PressureThese 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
